Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening
Alzheimer's & Dementia · 2023-04 · 19 (4) · 1393-1402
DOI: 10.1002/alz.12801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 23.09.2022. Verfasst von Christina Rabe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloidosis. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Further evidence is needed to support the use of plasma amyloid β (Aβ) biomarkers as Alzheimer's disease prescreening tools. This study evaluated the clinical performance and robustness of plasma Aβ 42 /Aβ 40 for amyloid positivity prescreening.
Methods
Data were collected from 333 BioFINDER and 121 Alzheimer's Disease Neuroimaging Initiative study participants. Risk and predictive values versus percentile of plasma Aβ 42 /Aβ 40 evaluated the actionability of plasma Aβ 42 /Aβ 40 , and simulations modeled the impact of potential uncertainties and biases. Amyloid PET was the brain amyloidosis reference standard.
Results
Elecsys plasma Aβ 42 /Aβ 40 could potentially rule out amyloid pathology in populations with low‐to‐moderate amyloid positivity prevalence. However, simulations showed small measurement or pre‐analytical errors in Aβ 42 and/or Aβ 40 cause misclassifications, impacting sensitivity or specificity. The minor fold change between amyloid PET positive and negative cases explains the biomarkers low robustness.
Discussion
Implementing plasma Aβ 42 /Aβ 40 for routine clinical use may pose significant challenges, with misclassification risks. Highlights Plasma Aβ 42 /Aβ 40 ruled out amyloid PET positivity in a setting of low amyloid‐positive prevalence. Including (pre‐) analytical errors or measurement biases caused misclassifications. Plasma Aβ 42 /Aβ 40 had a low inherent dynamic range, independent of analytical method. Other blood biomarkers may be easier to implement as robust prescreening tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, California, USA.
- F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- Roche Diagnostics GmbH, Mannheim, Germany.
- Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
- Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Zitieren
APA
Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., & Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study (2023). Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening. Alzheimer's & Dementia, 19(4), 1393-1402. https://doi.org/10.1002/alz.12801
Vancouver
Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M, et al. Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening. Alzheimer's & Dementia. 2023;19(4):1393-1402. doi:10.1002/alz.12801
BibTeX
@article{Rabe2023,
author = {Rabe, Christina and Bittner, Tobias and Jethwa, Alexander and Suridjan, Ivonne and Manuilova, Ekaterina and Friesenhahn, Michel and Stomrud, Erik and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar and Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study, Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study},
title = {Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {4},
pages = {1393--1402},
doi = {10.1002/alz.12801}
}
EUVIMED